El ácido tranexámico disminuye la mortalidad del shock hemorrágico traumático / Tranexamic acid therapy decreases mortality of traumatic hemorrhagic shock
Med. intensiva (Madr., Ed. impr.)
; 35(5): 286-287, jun.-jul. 2011.
Article
in Spanish
| IBECS
| ID: ibc-92808
Responsible library:
ES1.1
Localization: BNCS
RESUMEN
Un estudio aleatorizado, controlado con placebo y doble ciego, el CRASH 2, ha concluido, tras incluir a 20.211 traumatizados, que el ácido tranexámico reduce significativamente la mortalidad, tanto la global como la específicamente ligada a la perdida sanguínea severa.Consideramos que este es un avance terapéutico significativo, ya que por primera vez un fármaco se ha mostrado capaz de disminuir la letalidad del shock hemorrágico traumático. Dados los resultados, el elevado volumen de muertes por sangrado traumático que se producen en el mundo y la eficiencia del tranexámico, proponemos su uso compasivo hasta la inclusión de esta indicación en la ficha técnica (AU)
ABSTRACT
The CRASH 2, a randomized, double-blind, controlled trial, that enrolled 20,211adult trauma patients, has shown that the administration of tranexamic acid significantly reducesall-cause mortality and that specifically associated with severe blood loss as well.We consider it a significant therapeutic advance, because, for the first time, a drug has beendemonstrated to safely diminish mortality due to traumatic bleeding shock. On the basis of theseresults, and the high rate of death due to traumatic bleeding, we suggest that tranexamic acidshould be considered for compassionate use in bleeding trauma patients prior to its definitiveapproval for this medical condition (AU)
Full text:
Available
Collection:
National databases
/
Spain
Database:
IBECS
Main subject:
Shock, Hemorrhagic
/
Tranexamic Acid
Type of study:
Controlled clinical trial
Limits:
Humans
Language:
Spanish
Journal:
Med. intensiva (Madr., Ed. impr.)
Year:
2011
Document type:
Article
Institution/Affiliation country:
Hospital Universitario Virgen del Rocío/España